Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Insights - Corvus Pharmaceuticals, Inc. is set to present a corporate overview and conduct one-on-one meetings with investors at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - The presentation will be available via a live webcast, which can be accessed for 90 days post-event through the investor relations section of the Corvus website [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3] - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK, with additional clinical-stage candidates targeting multiple cancer indications [3]